Metformin for primary colorectal cancer prevention in patients with diabetes: A case-control study in a US population

Cancer

Volumn 121, Issue 7, 2015, Pages 1071-1078

  Sehdev, Amikar ^a   Shih, Ya Chen T ^b   Vekhter, Benjamin ^c   Bissonnette, Marc B ^b   Olopade, Olufunmilayo I ^b   Polite, Blase N ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

chemoprevention; colorectal cancer; diabetes; MarketScan database; metformin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; COLORECTAL CANCER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT; OVARY POLYCYSTIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; UNITED STATES; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FACTUAL DATABASE; FOLLOW UP; INCIDENCE; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROGNOSIS; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LONGITUDINAL STUDIES; MALE; METFORMIN; MIDDLE AGED; PRIMARY PREVENTION; PROGNOSIS; YOUNG ADULT;

EID: 84925356673     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29165     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R,. Diabetes and cancer. Endocr Relat Cancer. 2009; 16: 1103-1123.
3. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33: 1674-1685.
4. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108: 1167-1174.
5. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305.
6. Bailey CJ, Turner RC,. Metformin. N Engl J Med. 1996; 334: 574-579.
7. DeFronzo RA,. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999; 131: 281-303.
8. DeFronzo RA,. Pathogenesis of type 2 diabetes: implications for metformin. Drugs. 1999; 58 (suppl 1): 29-30; discussion 75-82.
9. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC,. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11: 20.
10. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM,. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-1625.
11. Currie CJ, Poole CD, Gale EA,. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-1777.
12. Garrett CR, Hassabo HM, Bhadkamkar NA, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012; 106: 1374-1378.
13. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27: 3297-3302.
14. Korsse SE, Peppelenbosch MP, van Veelen W,. Targeting LKB1 signaling in cancer. Biochim Biophys Acta. 2012; 1835: 194-210.
15. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010; 49: 662-671.
16. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010; 3: 1077-1083.
17. Pollak MN,. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012; 2: 778-790.
18. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010; 46: 2369-2380.
19. Pierotti MA, Berrino F, Gariboldi M, et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2013; 32: 1475-1487.
20. Rattan R, Ali Fehmi R, Munkarah A,. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012; 2012: 928127.
21. Lipkin M, Reddy B, Newmark H, Lamprecht SA,. Dietary factors in human colorectal cancer. Annu Rev Nutr. 1999; 19: 545-586.
22. National Cancer Institute. SEER-Medicare: Calculation of Comorbidity Weights. healthservices.cancer.gov/seermedicare/program/comorbidity.html. Accessed June 15, 2013.
23. Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008; 99: 2136-2141.
24. Tseng CH,. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 2012; 167: 409-416.
25. Surveillance, Epidemiology, and End Results Program, National Cancer Institute. SEER Stat Fact Sheets: Colon and Rectum Cancer. seer.cancer.gov/statfacts/html/colorect.html. Access date Nov 14, 2014.
26. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS,. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005; 294: 914-923.
27. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS,. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008; 134: 21-28.
28. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376: 1741-1750.
29. Yang YX, Hennessy S, Lewis JD,. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004; 127: 1044-1050.
30. Sehdev A, Shih YC, Huo D, Vekhter B, Lyttle C, Polite B,. The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Res. 2014; 34: 5043-5050.
31. Bodmer M, Becker C, Meier C, Jick SS, Meier CR,. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21: 280-286.
32. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3: 1451-1461.
33. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34: 2323-2328.
34. Noto H, Goto A, Tsujimoto T, Noda M,. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7: e33411.